Skip to main content
. 2019 Dec 17;25(1):15–18. doi: 10.1634/theoncologist.2019-0739

Figure 2.

Figure 2

Clinical responses to cryoablation followed by pembrolizumab. The largest cross‐section area of lesion was 7.2 cm × 6.8 cm before cryoablation (A); 2 weeks after the cryoablation 7.3 cm × 6.7 cm (B). After 1.5 months of pembrolizumab treatment, the patient achieved partial response with a significant reduction in the size of lesion, measuring 2.9 cm × 1.5 cm (C). The lesion was undetectable after 3 months of pembrolizumab treatment (D). The patient maintained complete response after 7 months of pembrolizumab treatment (E).